New York University sued the pharmaceutical company Pfizer for breach of contract in Manhattan Supreme Court on Thursday, arguing that the university is owed a portion of the sales of a drug used to treat lung cancer. 

The claim dates back to a 1991 agreement in which cancer-fighting technology was licensed to a startup called Sugen, which was founded by NYU scientists, William L. Mentlik of Lerner David Littenberg Krumholz & Mentlik, who is representing the university, wrote in Thursday’s complaint.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]